3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
53
Neoplasms
44
Prostatic Neoplasms
43
Breast Neoplasms
38
Neoplasm Metastasis
21
Unspecified Adult Solid Tumor, Protocol Specific
19
Lung Neoplasms
18
Head and Neck Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
16
Ovarian Neoplasms
15
Advanced Solid Tumors
11
Stomach Neoplasms
9
Sarcoma
9
Pancreatic Neoplasms
9
Solid Tumor
8
Melanoma
8
Esophageal Neoplasms
8
Carcinoma, Ovarian Epithelial
8
Urinary Bladder Neoplasms
7
Fallopian Tube Neoplasms
7
Colorectal Neoplasms
7
Small Cell Lung Carcinoma
6
Salivary Gland Neoplasms
6
Esthesioneuroblastoma, Olfactory
5
Esophageal Squamous Cell Carcinoma
5
Carcinoma, Renal Cell
5
Breast Neoplasms, Male
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Endometrial Neoplasms
4
Interventions
tremelimumab
3
durvalumab
3
Ipilimumab
3
pembrolizumab
2
Nivolumab
2
Carboplatin
2
poly ICLC
1
osimertinib
1
lenvatinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Vaccination
1
Peptides
1
Pemetrexed
1
Paclitaxel
1
Monophenol Monooxygenase
1
Melphalan
1
Docetaxel
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Docetaxel
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled